The fact that the percentage of patients treated with pioglitzone (a peroxisome proliferator-activated gamma receptor agonist that is highly effective in the treatment of insulin resistance but is associated with adverse events such as weight gain and retention of liquids) in group B increased from 8.0% at the beginning to 60.0% at the end of the follow-up could help to better understand the differences in the evolution of weight. Here, PPARG is linked to Insulin resistance.